Form 8-K · Current report
Johnson & Johnson 8-K, filed Jul 28, 2026
- Filed
- CIK
- 0000200406
- Accession no.
- 0000200406-26-000155
Summary
Johnson & Johnson announced a proposed comprehensive resolution of the remaining ovarian talc litigation with plaintiff firms leading the federal Multi-District Litigation and related state court proceedings, conditioned on participation of at least 95% of the remaining claims. The agreement includes a $5.5 billion commitment by J&J and follows an MDL court order requiring plaintiffs to show why remaining claims should not be dismissed for inability to prove specific causation.
Key points
- The proposed resolution is conditioned on participation of lead plaintiff firms representing at least 95% of the remaining ovarian talc claims.
- J&J committed $5.5 billion, with the first payment of no more than $3 billion to be made in 2027 and no additional payments due before 2028.
- On July 22, 2026, the MDL court ordered plaintiffs to show why the remaining pending talc claims should not be dismissed for inability to prove specific causation.
- J&J previously settled about 95% of filed mesothelioma lawsuits, all state consumer protection claims, and all talc-supplier disputes.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 7.01 Regulation FD Disclosure On July 27, 2026, the Company announced that it has reached an agreement for a comprehensive resolution of the ovarian talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned upon, among other things, the express participation of at least of 95% of the remaining claims. The agreement calls for per claim payments, with a $5.5 billion commitment by the Company, and the first payment of no more than $3 billion to be made in 2027 and no additional payments due before 2028. The press release further discussing this announcement is attached below as Exhibit 99.1. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.